Cargando…

Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage

BACKGROUND: NK cell cytotoxicity is regulated by the types of the interaction between killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands on target cells and the different binding affinity of the Fcγ receptor IIIA (CD16A) for IgG-coated tumor cells. Thus, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Canossi, Angelica, Aureli, Anna, Del Beato, Tiziana, Rossi, Piero, Franceschilli, Luana, De Sanctis, Flavio, Sileri, Pierpaolo, di Lorenzo, Nicola, Buonomo, Oreste, Lauro, Davide, Venditti, Adriano, Sconocchia, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983069/
https://www.ncbi.nlm.nih.gov/pubmed/27519478
http://dx.doi.org/10.1186/s12967-016-1001-y
_version_ 1782447854855389184
author Canossi, Angelica
Aureli, Anna
Del Beato, Tiziana
Rossi, Piero
Franceschilli, Luana
De Sanctis, Flavio
Sileri, Pierpaolo
di Lorenzo, Nicola
Buonomo, Oreste
Lauro, Davide
Venditti, Adriano
Sconocchia, Giuseppe
author_facet Canossi, Angelica
Aureli, Anna
Del Beato, Tiziana
Rossi, Piero
Franceschilli, Luana
De Sanctis, Flavio
Sileri, Pierpaolo
di Lorenzo, Nicola
Buonomo, Oreste
Lauro, Davide
Venditti, Adriano
Sconocchia, Giuseppe
author_sort Canossi, Angelica
collection PubMed
description BACKGROUND: NK cell cytotoxicity is regulated by the types of the interaction between killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands on target cells and the different binding affinity of the Fcγ receptor IIIA (CD16A) for IgG-coated tumor cells. Thus, it is conceivable that KIR and CD16A gene contents may contribute to the function of NK cells by modulating an immune response in the colorectal carcinoma (CRC) microenvironment. This hypothesis is supported by recent evidence suggesting that NK cells improve the clinical course of CRC patients by enhancing the anti-CRC effect of CD8 + T cells. This information provides the rationale to test the hypothesis whether the independent KIR segregation and specificity, as well as CD16A gene polymorphisms, have an impact on CRC. METHODS: Using polymerase chain reaction-sequence-specific primers (PCR-SSP) and sequence-based typing (SBT), we investigated KIR/HLA-C complex and CD16A (48H/R/L,158V/F) gene polymorphisms in 52 CRC patients and 61 local healthy controls (LCTRs). RESULTS: The allele frequency (AF) of at least five activating KIR (aKIRs) of the B haplotype (p = 0.036, OR 0.204), KIR2DL2 (p = 0.047, OR 0.2616), and KIR2DS2 genes (5.8 vs LCTR 13.8 % and vs. Fasano’s CTR 16.3 %, p = 0.05, OR 0.3145), in the absence of their cognate HLA-C1 ligands, were significantly associated with a reduced genetic risk of CRC. In contrast, CD16A-48H polymorphism was positively associated with an increased genetic risk of CRC (p = 0.05, OR 2.761). The latter was also found to be correlated with advanced stages of disease [III and IV (p = 0.03, OR 3.625)]. CONCLUSIONS: Our data suggest that the analysis of aKIRs and KIR2DL2 gene and CD16A-48H may be of interest for the identification of individuals at reduced and increased genetic risk of CRC, respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-1001-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4983069
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49830692016-08-14 Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage Canossi, Angelica Aureli, Anna Del Beato, Tiziana Rossi, Piero Franceschilli, Luana De Sanctis, Flavio Sileri, Pierpaolo di Lorenzo, Nicola Buonomo, Oreste Lauro, Davide Venditti, Adriano Sconocchia, Giuseppe J Transl Med Research BACKGROUND: NK cell cytotoxicity is regulated by the types of the interaction between killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands on target cells and the different binding affinity of the Fcγ receptor IIIA (CD16A) for IgG-coated tumor cells. Thus, it is conceivable that KIR and CD16A gene contents may contribute to the function of NK cells by modulating an immune response in the colorectal carcinoma (CRC) microenvironment. This hypothesis is supported by recent evidence suggesting that NK cells improve the clinical course of CRC patients by enhancing the anti-CRC effect of CD8 + T cells. This information provides the rationale to test the hypothesis whether the independent KIR segregation and specificity, as well as CD16A gene polymorphisms, have an impact on CRC. METHODS: Using polymerase chain reaction-sequence-specific primers (PCR-SSP) and sequence-based typing (SBT), we investigated KIR/HLA-C complex and CD16A (48H/R/L,158V/F) gene polymorphisms in 52 CRC patients and 61 local healthy controls (LCTRs). RESULTS: The allele frequency (AF) of at least five activating KIR (aKIRs) of the B haplotype (p = 0.036, OR 0.204), KIR2DL2 (p = 0.047, OR 0.2616), and KIR2DS2 genes (5.8 vs LCTR 13.8 % and vs. Fasano’s CTR 16.3 %, p = 0.05, OR 0.3145), in the absence of their cognate HLA-C1 ligands, were significantly associated with a reduced genetic risk of CRC. In contrast, CD16A-48H polymorphism was positively associated with an increased genetic risk of CRC (p = 0.05, OR 2.761). The latter was also found to be correlated with advanced stages of disease [III and IV (p = 0.03, OR 3.625)]. CONCLUSIONS: Our data suggest that the analysis of aKIRs and KIR2DL2 gene and CD16A-48H may be of interest for the identification of individuals at reduced and increased genetic risk of CRC, respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-1001-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-12 /pmc/articles/PMC4983069/ /pubmed/27519478 http://dx.doi.org/10.1186/s12967-016-1001-y Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Canossi, Angelica
Aureli, Anna
Del Beato, Tiziana
Rossi, Piero
Franceschilli, Luana
De Sanctis, Flavio
Sileri, Pierpaolo
di Lorenzo, Nicola
Buonomo, Oreste
Lauro, Davide
Venditti, Adriano
Sconocchia, Giuseppe
Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title_full Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title_fullStr Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title_full_unstemmed Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title_short Role of KIR and CD16A genotypes in colorectal carcinoma genetic risk and clinical stage
title_sort role of kir and cd16a genotypes in colorectal carcinoma genetic risk and clinical stage
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4983069/
https://www.ncbi.nlm.nih.gov/pubmed/27519478
http://dx.doi.org/10.1186/s12967-016-1001-y
work_keys_str_mv AT canossiangelica roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT aurelianna roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT delbeatotiziana roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT rossipiero roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT franceschilliluana roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT desanctisflavio roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT sileripierpaolo roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT dilorenzonicola roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT buonomooreste roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT laurodavide roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT vendittiadriano roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage
AT sconocchiagiuseppe roleofkirandcd16agenotypesincolorectalcarcinomageneticriskandclinicalstage